MET and lung adenocarcinoma: To further investigate the antitumor efficacy of WntSI in patients with NSCLC, we established a patient‐derived xenograft (PDX) model of lung adenocarcinoma harboring EGFR mutation and MET amplification in NOD/SCID mice (Figure 7A).